A new drug that works by making tumors more susceptible to chemotherapy and the immune system has increased survival in those ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

For more than two decades, oncologists treating advanced pancreatic cancer have watched new drugs fail to move the survival ...

Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase ...

A new pill could be the future of treatment late-stage pancreatic cancer in the U.S., nearly doubling the length patients ...

A homegrown Northwestern drug is giving Chicago-area families something they almost never get with metastatic pancreatic ...

A pancreatic cancer drug is showing promising signs of a possible breakthrough after a clinical trial found it nearly doubled ...

Daraxonrasib delivered a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy in previously ...

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a ...

An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...